Edgewise Therapeutics【EWTX】株式ニュース

名称	銘柄コード	市場	種別
Edgewise Therapeutics Inc	EWTX	NASDAQ	普通株式

	前日比	前日比 %	現在値	時刻
	-0.37	-2.11%	17.13	09:00:00

始値	安値	高値	終値	前日終値
17.65	17.03	17.905	17.13	17.50

この銘柄の詳細情報 »

最新ニュース

日付	時間	ソース	タイトル
2024/5/10	22:10	EDGAR2	Form 8-K - Current report
2024/5/10	22:07	EDGAR2	Form S-3ASR - Automatic shelf registration statement of..
2024/5/10	21:00	BW	Edgewise Therapeutics to Present at the RBC Capital Markets..
2024/5/09	22:21	EDGAR2	Form S-8 - Securities to be offered to employees in employee..
2024/5/09	21:06	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/5/09	21:00	EDGAR2	Form 8-K - Current report
2024/5/09	21:00	BW	Edgewise Therapeutics Reports First Quarter 2024 Financial..
2024/5/07	22:16	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
2024/5/07	22:14	EDGAR2	Form 8-K - Current report
2024/5/07	21:00	BW	Edgewise Therapeutics Appoints Arlene Morris to its Board of..
2024/5/06	21:00	BW	Edgewise Therapeutics Doses First Patient in Phase 2..
2024/4/23	21:00	BW	Edgewise Receives European Medicines Agency (EMA) Orphan..
2024/4/16	05:05	BW	Edgewise Therapeutics Announces Positive Two-Year Topline..
2024/3/28	21:00	BW	Edgewise Therapeutics Announces Upcoming Podium Presentation..
2024/3/27	21:00	BW	Edgewise Therapeutics to Present at the Cantor Virtual..
2024/3/05	22:00	BW	Edgewise Therapeutics to Present at the Leerink Partners..
2024/2/28	22:00	BW	Edgewise Therapeutics to Present on EDG-5506 for the..
2024/2/22	22:07	EDGAR2	Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2024/2/22	22:00	EDGAR2	Form 8-K - Current report
2024/2/22	22:00	BW	Edgewise Therapeutics Reports Fourth Quarter and Full Year..
2024/2/14	22:43	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/13	22:00	BW	Edgewise Receives U.S. FDA Fast Track Designation for..
2024/2/10	07:42	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2024/2/08	06:15	EDGAR2	Form 144 - Report of proposed sale of securities
2024/1/20	06:54	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/1/19	22:44	EDGAR2	Form 8-K - Current report
2024/1/19	22:37	BW	Edgewise Therapeutics Announces Pricing of $240 Million..
2024/1/19	20:05	EDGAR2	Form 8-K - Current report
2024/1/19	20:04	EDGAR2	Form S-3MEF - Registration adding securities to prior Form..
2024/1/19	20:02	EDGAR2	Form 424B3 - Prospectus [Rule 424(b)(3)]
2024/1/09	22:39	BW	Edgewise Therapeutics Highlights 2023 Accomplishments and..
2023/12/29	06:38	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2023/12/27	06:32	EDGAR2	Form 144 - Report of proposed sale of securities
2023/12/19	22:00	BW	Edgewise Therapeutics to Present at the 42nd Annual J.P...
2023/12/18	22:00	BW	Edgewise Therapeutics Launches First of Its Kind Educational..
2023/11/30	22:56	DJN	Edgewise Gets FDA Orphan, Rare-Pediatric-Disease..
2023/11/30	22:00	BW	Edgewise Receives Orphan Drug and Rare Pediatric Disease..
2023/11/09	22:05	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/09	22:00	EDGAR2	Form 8-K - Current report
2023/11/09	22:00	BW	Edgewise Therapeutics Reports Third Quarter 2023 Financial..
2023/11/08	22:00	BW	Edgewise Therapeutics to Present at Upcoming Investor..
2023/11/01	21:00	BW	Edgewise to Present Data on EDG-7500 at the American Heart..
2023/10/26	21:00	BW	Edgewise Therapeutics Announces Expansion of their EDG-5506..
2023/9/27	21:00	BW	Edgewise Therapeutics to Present on EDG-5506 for Becker..
2023/9/26	21:00	BW	Edgewise Therapeutics Announces Initiation of GRAND CANYON,..
2023/9/14	21:00	BW	Edgewise Therapeutics Begins Dosing First-in-Human Phase 1..
2023/8/19	08:13	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2023/8/19	08:13	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2023/8/10	21:01	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/10	21:00	EDGAR2	Form 8-K - Current report